THERACRYF PLC - Half year results for the six months to 30 September 2025

In this episode, we examine Theracryf PLC, an AIM-listed biotech company undergoing a significant strategic shift to expedite shareholder value. The focus is on their lead asset, OX-1, an orexin-1 blocker aimed at addressing substance use disorders through a targeted approach that minimizes side effects. The company operates as a virtual entity, concentrating on early proof of concept before licensing their technology to larger pharmaceutical firms, thereby reducing their risk and costs. Additionally, we explore their second asset, a dopamine modulator for managing chronic fatigue in multiple sclerosis patients. Join us as we unpack their execution strategy, funding status, and potential for future growth.